HT
NRXP icon

Headlands Technologies’s NRX Pharmaceuticals NRXP Stock Holding History

Headlands Technologies’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,394
Closed -$83.9K – 909
2026
Q1 		$83.9K Buy
+39,394
New +$79.5K 0.01% 674

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Headlands Technologies's NRXP Position: Q2 2026 in Review

Headlands Technologies sold out of NRX Pharmaceuticals (NRXP) in Q2 2026, closing a stake of 39,394 shares — an estimated $83.9K sold.

Headlands Technologies first reported a position in NRXP in Q1 2026 and held it in 1 quarter. The position peaked at $83.9K in Q1 2026. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Headlands Technologies reported no remaining NRX Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 39,394 NRX Pharmaceuticals shares in Q2 2026, an estimated $83.9K.
  • Headlands Technologies first reported a position in NRX Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Headlands Technologies's NRX Pharmaceuticals position peaked at $83.9K in Q1 2026.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.